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We explored novel functions of tenascin-C by comparing mouse embryonic ﬁbroblasts (MEFs) pro-
ﬁcient or deﬁcient in tenascin-C expression. Transcript proﬁling analysis identiﬁed tissue plasmin-
ogen activator (tPA) as the most consistently over-expressed gene in all tenascin-C deﬁcient MEFs.
This was conﬁrmed by real-time PCR as well as by protein expression analysis. In agreement with
these observations, tenascin-C deﬁcient MEFs had an increased capacity to digest ﬁbrin in situ. Con-
sistently, tenascin-C expression in vivo was found to correlate with ﬁbrin deposition in several dis-
eases associated with tenascin-C overexpression such as ﬁbrosis, asthma and cancer. In conclusion,
the present study suggests a new role of tenascin-C as a regulator of the ﬁbrinolytic system.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tenascin-C is a multimeric extracellular matrix glycoprotein ex-
pressed during tissue generation and remodeling. It is widely
found during embryogenesis, whereas its expression is restricted
in the adult in a normal physiological situation. However, in partic-
ular conditions characterized by notable modiﬁcations of tissue
composition, such as in asthma, ﬁbrosis, inﬂammation, wound
healing and cancer, tenascin-C is known to be highly re-expressed
(for review see [1,2]). Interestingly, in contrast to other tenascins
which have stabile expression patterns, tenascin-C, together with
the last described tenascin member, tenascin-W, has been reported
to be tightly regulated by the tissue environment (for review see
[3]). In turn, tenascin-C enrichment in the extracellular compart-
ment is sensed by cells contacting this matrix and they respond
to this signal by modifying their gene expression proﬁle. For in-
stance, a set of de-adhesion, angiogenesis, and wound healing
regulators were identiﬁed as tenascin-C dependent targets in
striated muscle [4]. Furthermore, analysis of glioblastoma cellschemical Societies. Published by E
her Institute for Biomedical
strasse 66, CH-4058 Basel,
r).grown in presence of tenascin-C has revealed that tenascin-C trig-
gers destabilization of actin stress ﬁbers through down-regulation
of tropomyosin-1 and stimulates both endothelin receptor type A
associated mitogen-activated protein kinase and Wnt signaling
pathways [5].
In the present study, we sought to investigate which signaling
pathways may be activated by tenascin-C. Transcriptome compar-
ison of tenascin-C proﬁcient and tenascin-C deﬁcient cells surpris-
ingly revealed tissue plasminogen activator (tPA) as the top gene
upregulated in the absence of tenascin-C when sorted in terms of
statistical signiﬁcance (P < 105). Together with urokinase plas-
minogen activator, tPA has as its main function the generation of
plasmin from plasminogen. The phenotypic analysis of plasmino-
gen- or ﬁbrinogen-deﬁcient mice as well as double knock out mice
suggested that the fundamental and possibly only essential physi-
ological role of plasminogen is ﬁbrinolysis, i.e. proteolysis of ﬁbrin
into ﬁbrin degradation product [6]. Consistently, we found that
ﬁbrinolysis was increased in TNC-deﬁcient mouse embryonic
ﬁbroblasts (MEFs) compared to TNC-producing MEFs in situ. Final-
ly, to test the physiological relevance of these ﬁndings, we investi-
gated several conditions (asthma, ﬁbrosis, and cancer) that are
associated with tenascin-C overexpression to assess whether accu-
mulation of tenascin-C and accumulation of ﬁbrin may be linked in
these contexts.lsevier B.V. All rights reserved.
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2.1. Cell culture
Mouse embryonic ﬁbroblasts (MEFs) from wild-type (WT) and
tenascin-C knock-out (TNCKO) [7] mice were a kind gift from
Johannes Schittny (Bern, Switzerland). They were obtained at pas-
sage 3 and cultured in DMEM medium containing 10% fetal bovine
serum (Sigma). Cells were plated at 1  105 to 3  105 cells per
p100 dish and subcultured 5–8 days later. Population doublings
per passage was calculated as log 2 (number of cells at time of sub-
culture/number of cells plated) as previously described [8]. Cumu-
lative population doubling was plotted against total time in culture
to assess crisis (visualized as a plateau) and subsequent immortal-
ization (restart of the curve) of the cells. Spontaneously immortal-
ized MEFs from WT mice were transfected with short hairpin RNA
(shRNA) against mouse tenascin-C (Sigma) using Nucleofactor
technology (Lonza, Köln, Germany). Control clones were transfec-
ted with an empty vector. MEFs were then selected with 2 lg/ml
puromycin and cloned with glass cloning cylinders. Clones of
interest were screened by Western blot analyses of conditioned
media.2.2. Immunocytochemistry
Ten thousand MEFs were seeded into chambers of 8-well Cul-
tureSlides (BD Bioscience). The next day, cells were ﬁxed for
15 min in Formaﬁx (Shandon) and, after three washes with PBS,
permeabilized for 10 minutes in 0.5% Triton. Cells were then incu-
bated for 1 h at RT with anti-vinculin antibody (1/400, V9131, Sig-
ma, Buchs, Switzerland), washed three times with PBS and
incubated for 1 h at RT with Alexa Fluor 546-labeled phalloidin
(1/200, Sigma), Alexa Fluor 488-labeled goat anti-rat IgG (1/200,
Invitrogen, Basel, Switzerland) and Hoechst 33258 bisbenzimide
(10 lg/ml, Sigma). Cells were washed three times with PBS and
mounted in Prolong Gold antifade reagent (Invitrogen, Basel, Swit-
zerland). Wide-ﬁeld images were acquired using a Zeiss Axiovert
200 microscope equipped with a charge-coupled device Cool Snap
HQ camera, using a 40/1.3 oil objective (Carl Zeiss, Oberkochen,
Germany).
2.3. RNA isolation and transcript proﬁling
RNA was isolated using QiaShredder (Qiagen) and the RNeasy
kit (Qiagen) according to the manufacturer’s protocol. RNA was
converted into labelled cRNA and hybridized to Affymetrix mouse
1.0 oligonucleotide arrays. Two groups of cells were compared: the
ﬁrst one comprising three independent wild-type clones express-
ing tenascin-C and the second one comprising four independent
clones which did not secrete tenascin-C according to Western blot
analysis. Among these four clones, two were originating from WT
MEFs stably transfected by shRNA against mTNC, and two from
TNCKO MEFs based on the assumption that duplicating the source
of TNC-deﬁcient MEFs would eliminate the risk of detecting intrin-
sic properties of the analyzed clones unrelated to the tenascin-C
deﬁciency. Raw data was read with the AFFY packages from the
Bioconductor 2.4 release. Differentially expressed genes were iden-
tiﬁed using the empirical Bayes method (F-test) implemented in
the LIMMA package. Contrasts were calculated between groups
using an adjusted P-value of 0.05 (with Benjamin–Hochberg false
discovery correction), a minimum absolute linear fold change dif-
ference of 1.5 and a minimum average expression value of 5.0
(log 2). The R analysis script is available upon request. Microarray
data are deposited into the Gene Expression Omnibus (GEO) public
database (GSE23547).2.4. RT and QPCR
For quantitative PCR, isolated RNA were ﬁrst treated with RQ1
DNase (Promega), and then reverse transcribed with the Thermo-
Script™ RT-PCR System (Invitrogen) according to the supplied pro-
tocol using 2 lg RNA in a 20 ll setup with oligo dT primers. The
generated cDNA was then used for quantitative real-time PCR
using Platinum SYBR Green qPCR SuperMix-UDG with ROX
(Invitrogen) on an Abi7000 (Applied Biosystems). The primers used
for qPCR are listed in Supplementary Table 1. For each clone, three
experiments were performed in triplicates. Values were normal-
ized to GAPDH and fold changes calculated using the efﬁciency
DDct method.
2.5. Western blot analysis
Serum-free cell culture medium was collected and normalized
against the number of cells seeded. Samples were then separated
by SDS–PAGE and electroblotted to polyvinyldiﬂuoride mem-
branes (Millipore, Billerica, MA, USA). After a blocking step in 5%
milk, membranes were incubated with rabbit polyclonal antiserum
raised against tissue plasminogen activator (ASMTPA-GF-HT,
1:2500, Molecular innovations, Novi, MI, USA), rat monoclonal
antibody Mtn12 [9] raised against mouse tenascin-C (1:50, culture
supernatant kindly provided by Susan Schenk). They were then
incubated for 1 h with anti-rabbit or anti-rat IgG coupled to horse-
radish peroxidase. Blots were developed using ECL reagent (GE
Healthcare, Otelﬁngen, Switzerland) and exposed to Kodak BioMax
MR Films (Kodak, Rochester, NY, USA). Intensities of the bands
were quantiﬁed using ImageJ software (http://www.rsb.info.nih.-
gov/ij/).
2.6. Quantiﬁcation of tPA and uPA activities
Mouse embryonic ﬁbroblasts (0.1 M)were seeded inwells of six-
well plates and cultured for 2 days, incubatedwith serum-freemed-
ium for 24 h and conditioned medium was collected to measure
enzymatic activities. Quantiﬁcation of tPA and uPA activities was
performed using ‘‘spectrozyme’’ and ‘‘spectrolyse’’ activity assays
kits from America Diagnostica (Pfungstadt, Germany), respectively,
according to the manufacturer instructions. For elaboration of stan-
dard curves, two-chain recombinant tissue plasminogen activator
and human urokinase with enzymatic units calibrated against
WHO standardswere purchased fromAmerica Diagnostica (Pfungs-
tadt, Germany). Experiments were performed twice in triplicates.
2.7. Fibrinolysis assays
Fibrinolysis assays were performed as previously described
[10]. A ﬁbrin–agarose matrix was prepared with 1.2% of low-melt-
ing agarose (Sigma), 12 mg/ml ﬁnal concentration of ﬁbrinogen
(F4883, Sigma), and 0.25 U/ml ﬁnal concentration of thrombin
(T9549, Sigma). Gels were poured into wells of 24-wells and 6-
wells plates, using 0.5 and 3 ml, respectively. After 90–120 min
of polymerization, gels were perforated with the upper part of a
1-ml cell culture pipette and 15 ll of a 1  106 ml1 cell solution
seeded in each hole. The next day, serum-free medium was added
to the cultures to avoid drying of the gel. Gels were scanned 24 h
later and images processed using ImageJ software (http://
www.rsb.info.nih.gov/ij/) for quantiﬁcation of the area digested
by the cells. Experiments were performed 3 times in duplicates.
2.8. Human biopsies
Squamous cell carcinoma of the head and neck region samples
were obtained from the University Department of Yeditepe,
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vided as tissue multi-arrays (TMA) by the University Hospital of
Basel. Lung biopsies from asthmatic patients were collected during
bronchoscopy. The experiments were undertaken with the under-
standing and written consent of patient and according to ethical
principles, including the World Medical Association Declaration
of Helsinki.2.9. In vivo experiments
C57BL/6 mice were bred in the animal facility of the Transge-
nose Institute (CNRS, Orleans, France). For experiments, adult (6–
10 weeks old) animals were kept in sterile, isolated ventilated
cages. All animal experiments complied with the French Govern-
ment’s ethical and animal experiment regulations and were ap-
proved by the Comité Régional d’Ethique pour l’Expérimentation
Animale (Tours, France). All animals had access to water and food
ad libidum throughout the experiments. Bleomycin sulfate from
Bellon Laboratories was given at 5 mg/kg in saline, or saline alone
to 5 mice each by nasal instillation in a volume of 40 ll under light
ketamine–xylasine anesthesia. After 1 and 14 days, lungs were
either processed for preparation of supernatants after homogeniza-
tion as described previously [11] or embedded in OCT for prepara-
tion of cryosections.
2.10. Immunohistochemistry
Immunostainings and chromogenic detections were performed
using the Discovery XT system (Ventana Medical Systems, Tucson,
AZ, USA). For parafﬁn sections of head and neck squamous cell car-
cinomas and lung biopsies of asthmatic patients, antigen retrieval
was achieved in protease buffer 1 (Ventana) for 4 min and protease
buffer 2 (Ventana) for 12 min for ﬁbrin and for tenascin-C, respec-
tively. Frozen TMA slides and mouse cryosections were dried 1 h at
room temperature, ﬁxed for 10 min at 4 C in acetone, and then
introduced into the automate. Slides were incubated for 1 h at
37 C with the goat anti-rat ﬁbrinogen antibody (Cappel, 1:1000),
the B28-13 anti-human tenascin-C antibody [12], 1:500) or with
the Mtn12 anti-mouse tenascin-C antibody (1:50). They were then
treated for 32 min at 37 C with a biotinylated anti-goat, anti-
mouse and anti-rat secondary antibody, respectively (Jackson
Immunoresearch laboratories) and developed with 3,30-diam-
inobenzidine (DAB) Map detection kit (Ventana). Counterstainings
were obtained with hematoxylin and bluing reagent (Ventana).
Wide-ﬁeld images were acquired using a Leica Z6 MacroFluo
microscope using a 20/0.50 objective (Carl Zeiss, Oberkochen,
Germany).
3. Results and discussion
3.1. Development and analysis of tenascin-C deﬁcient and producing
MEF cell lines
Primary mouse embryonic ﬁbroblasts expanded from wild-type
mice (WT MEFs) do express and secrete tenascin-C endogenously
at rather high levels (see Fig. 1A). To analyze changes in the gene
expression proﬁle triggered by tenascin-C deﬁciency, we prevented
tenascin-C expression in MEFs by two different approaches. First,
MEFs expanded from tenascin-C knock-out mice (TNC KO) were
spontaneously immortalized and cloned. Second, a set of short
hairpin RNAs against mouse tenascin-C were stably integrated into
spontaneously immortalized WT MEFs. Conditioned medium of
more than 30 clones were analyzed by Western blot and clones
with undetectable levels of tenascin-C were selected for further
experiments. In parallel, control WT MEFs were stably transfectedwith an empty vector and cloned. Fig. 1A conﬁrms the accumula-
tion of high levels of tenascin-C in culture medium of clones from
parental MEFs and undetectable levels of tenascin-C in the culture
medium of TNC-deﬁcient MEFs.
Microscopic observation of TNC-deﬁcient MEFs revealed that
absence of tenascin-C triggered striking changes in cell morphol-
ogy (Fig. 1B). TNC-deﬁcient MEFs were much more spread than
theWTMEFs. Furthermore, vinculin staining of both groups of cells
revealed many more focal adhesions in TNC-deﬁcient MEFs com-
pared to TNC-producing MEFs (Fig. 1B). Since cell adhesion and cell
proliferation are tightly linked processes, we analyzed the growth
rate of both groups of cells by calculating the population doubling
after each passage for each cell population starting at the time
when clones were established. This showed that TNC-producing
MEFs have a higher proliferation rate than TNC-deﬁcient MEFs
(Fig. 1C). Within each group, the growth rate was linear, showing
that tenascin-C triggered a stable proliferation advantage to the
cells.
3.2. Main signaling pathways associated with tenascin-C
In order to identify new ways of action of tenascin-C, we com-
pared expression proﬁles of 3 TNC-producing MEF clones and 4
TNC-deﬁcient MEF clones and identiﬁed differentially expressed
genes using the Bioconductor 2.4 release (see Supplementary Table
2). As a validation of the method, tenascin-C was the most highly
down-regulated gene in TNC-deﬁcient MEFs, with a fold change
of more than 12 and a P-value approaching 104. We selected
the best candidate genes in terms of fold change, P-values, and rel-
evance in cancer and compared their expression level by real-time
PCR in extended groups of TNC-producing (4 clones) and TNC-deﬁ-
cient MEFs (6 clones) to verify the micro-array results (Table 1).
This analysis indicates at least three important signaling path-
ways potentially modulated by tenascin-C: TGF-beta, HGF/c-MET
andWnt signaling. Follistatin, a known inhibitor of activins (signal-
ing molecules from the TGF-beta family regulating growth and
metastasis of cancer cells [13]) is upregulated in TNC-deﬁcient
MEFs. In agreement, gene expression proﬁle analysis of T98G glio-
blastoma cells revealed downregulation of follistatin when these
cells were cultured on a tenascin-C rich matrix [5]. We found
c-MET, the receptor of hepatocyte growth factor, down-regulated
in TNC-deﬁcient MEFs, which is consistent with the observation
that tenascin-C regulates c-MET function in mammary epithelial
tissue [14]. Furthermore, tenascin-C and c-MET have been shown
to act in concert to stimulate invasion of colon cancer cells [15].
Finally, we showed that Dickkopf homolog 2 (Dkk2) is downregu-
lated in TNC-deﬁcient MEFs. Dkk proteins are known to modulate
Wnt pathways, most of the members of this family being inhibitors
of the pathway, except Dkk2 which has also been described as an
activator of Wnt signaling (for review, see [16]). Since Dkk1 and
Dkk2 are expected to have opposite effects, our results are
strengthening the ﬁnding by Ruiz et al. who showed that Dkk1 is
downregulated by TNC [5].
3.3. Increase of tissue plasminogen activator protein and activity level
in absence of TNC
We then focused our study on tPA since, although rather unex-
pected, its differential expression in TNC-producing versus TNC-
deﬁcient MEFs was found with very high conﬁdence (P < 105
and P < 104 according to micro-arrays and real-time PCR experi-
ments, respectively). Comparison of conditioned medium collected
from the two groups of cells revealed a 1.69-fold increase of tPA
protein levels (P < 0.05, ANOVA test) (Fig. 2A) and a 2-fold increase
of tPA activity (Fig. 2B) in TNC-deﬁcient MEFs. In contrast, activity
level of urokinase plasminogen activator (uPA) was not signiﬁ-
Fig. 1. Cell culture features of tenascin-C producing MEFs and tenascin-C deﬁcient MEFs. (A) Immunoblot analysis of tenascin-C secreted by TNC-producing (TNC+) and TNC-
deﬁcient MEFs (TNC). Culture media were collected after conﬂuency and Western blot was performed with a TNC antibody. (B) Immunocytochemical analysis of TNC+ and
TNC MEFs. MEFs seeded at very low density were stained for vinculin (in green) and actin (in red). Hoechst reagent was used to stain nuclei. One representative picture is
shown for each group. (C) Replication characteristics of TNC+ MEFs (in black) and TNC MEFs (in grey). Cells were counted at each passage. Population doublings were
calculated and plotted against time. ⁄⁄P < 0.001.
Table 1
Key differentially expressed genes (TNC-deﬁcient versus TNC-proﬁcient MEFs).
Fold change
Micro-arrays Real-time PCR
Genes up-regulated in TNC-deﬁcient MEFs
Tissue plasminogen activator 2.06*** 3.01***
Follistatin 3.66* 5.10**
Osteoglycin 5.29* 3.68*
Selenoprotein P 2.79** 4.69***
Lysyl oxidase-like 2 3.99** 4.68***
ADAMTS4 1.56* 2.63**
Genes down-regulated in TNC-deﬁcient MEFs
Phospholipase A2 1.61** 1.58**
Dual speciﬁcity phosphatase 9 1.58** 2.10**
c-MET 1.53* 1.87**
Dickkopf homolog 2 2.18*** 3.57***
* P < 0.05.
** P < 0.005.
*** P < 0.0005.
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that tenascin-X deﬁciency induced matrix metalloproteinase 2
through the c-JUN N-terminal kinase and protein tyrosine kinase
phosphorylation pathway [17]. However, in contrast to their obser-
vations, we were not able to induce down-regulation of tPA by
acute addition of tenascin-C in the medium or as substrate for
TNCKO MEFs, suggesting that regulation of tPA by tenascin-C re-
quires a long-term, indirect process.
3.4. Increase of plasmin activity by TNC-deﬁcient MEFs
tPA is a serine proteinase which converts the inactive proen-
zyme plasminogen into the active enzyme plasmin. In turn, plas-
min degrades ﬁbrin, its main substrate, thus playing a key role in
the regulation of blood ﬁbrinolysis (for review see [18]). To assess
whether TNC-deﬁcient MEFs showed enhanced ﬁbrinolytic capac-
ity, we seeded equal numbers of MEFs into small holes perforated
in a ﬁbrin gel, and observed the expanding digested area around
the cells. After 48 h, the digested ﬁbrin gel was almost twice wider
Fig. 2. Tissue plasminogen activator protein and activity levels in TNC-proﬁcient versus TNC-deﬁcient MEFs. (A) Western blot analysis of tPA content in conditioned media
collected from TNC+ and TNCMEFs. Cells were cultured for 3 days and starved for 24 h in serum-free medium before collection of the medium. Quantiﬁcations of the band
intensities are indicated below each lane. (B) tPA activities measured in TNC+ and TNCMEFs using a speciﬁc substrate. (C) uPA activities measured in TNC+ and TNCMEFs
using a speciﬁc substrate. (D and E) ﬁbrinolysis assays performed on TNC+ and TNCMEFs. A representative picture is shown in (D) and a graph showing measured digested
areas is presented in (E) (means of three independent experiments performed in duplicates on ﬁve different clones). (F) Scheme representing the steps leading to the
correlation between tenascin-C overexpression and ﬁbrin deposition.
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sentative picture in Fig. 2D and quantiﬁcation in Fig. 2E). This
experiment revealed that, as expected from the direct tPA activity
measurements, TNC-deﬁcient MEFs had a higher ﬁbrinolytic
capacity than TNC-producing cells. In view of our in vitro ﬁndings
(summarized in Fig. 2F), we considered a correlation between ten-
ascin-C and ﬁbrin deposition in diseases such as asthma, ﬁbrosis
and cancer at locations of high tenascin-C expression.
3.5. Tenascin-C and ﬁbrin in ﬁbrotic and asthmatic diseases
To model injury induced chronic inﬂammation and trigger pul-
monary ﬁbrosis [11], we treated mice with 5 mg/kg bleomycin or
with NaCl and analyzed their lung protein content byWestern blot.
One day after the start of the treatment, tenascin-C was expressedat very low levels in both control and bleomycin-treated mice
(Fig. 3A). In contrast, at day 14, lungs from bleomycin-challenged
mice harbored very high expression of tenascin-C (Fig. 3B), as ex-
pected [19]. Immunohistochemical analysis of lung cryosections
from control and bleomycin-challenged mice conﬁrmed the accu-
mulation of tenascin-C in the ﬁbrotic tissues (Fig. 3C).
We also analyzed bronchial biopsies of three asthmatic patients
and observed strong deposition of ﬁbrin in proximity of blood cap-
illaries (see Fig. 4 for representative picture), in contrast to a con-
trol lung sample devoid of ﬁbrin (data not shown). This suggests
that ﬁbrinogen having extravasated from blood capillaries which
are known to be increased in asthmatic diseases [20] has been ac-
tively converted into a ﬁbrin network which has not been further
degraded. The status of ﬁbrin in lungs from asthmatic patients is
poorly described but our observation that ﬁbrin accumulates in
Fig. 3. Expression of tenascin-C and ﬁbrin in lungs from bleomycin challenged mice. (A and B) Western blot analysis of tenascin-C content in supernatants from homogenized
lungs coming from NaCl and bleomycin-treated mice (BLEO and BLEO+, respectively) 1 day (A) and 14 days (B) after beginning of the treatment. Five mice per group were
tested. (C) Immunohistochemical detection of tenascin-C and ﬁbrin in lungs from NaCl and bleomycin-treated mice 14 days after beginning of the treatment. Left panel shows
hematoxylin and eosin staining (HE), middle panel tenascin-C staining and right panel ﬁbrin staining. Insets in the right panel shows the slight unspeciﬁc staining obtained in
the absence of primary antibody. Bar: 50 lm.
Fig. 4. Immunohistochemical detection of tenascin-C and ﬁbrin in lungs from asthmatic patients. Lung biopsies from asthmatic patients were collected during bronchoscopic
examination. Left panel shows hematoxylin and eosin staining (HE), middle panel tenascin-C staining and right panel ﬁbrin staining. Bar: 50 lm.
918 F. Brellier et al. / FEBS Letters 585 (2011) 913–920this pathology is in agreement with a previous study reporting that
severe asthma is associated with an anti-ﬁbrinolytic environment
in the airways [21]. Consistent with an earlier report [22], we
found tenascin-C speciﬁcally expressed in the airways of asthmatic
patients. More precisely, it was observed in the sub-epithelial tis-
sue directly adjacent to tenascin-C expressing stromal cells (Fig. 4).
Targeting the ﬁbrinolytic system may be considered as a thera-
peutical approach in both asthmatic and ﬁbrotic diseases. Consis-
tently, re-equilibrating the ﬁbrinolytic balance following
bleomycin-induced lung inﬂammation with urokinase plasmino-
gen activator attenuates symptoms of the disease [23]. Also, in amouse model of asthma, aerosolized tissue-type plasminogen acti-
vator signiﬁcantly diminished airway hyperresponsiveness [24].
Importantly, tenascin-C plays an active role in the development
of asthmatic and ﬁbrotic diseases since TNCKO mice are less prone
to allergen-induced bronchial asthma [25] and to liver ﬁbrosis in
immune-mediated chronic hepatitis [26]. With regard to our
in vitro and in situ observations, we postulate that in TNCKO mice,
the ameliorated asthma and ﬁbrotic phenotypes may be due to in-
creased ﬁbrinolysis. In view of these ﬁndings, targeting tenascin-C
in asthmatic and ﬁbrotic diseases may be a promising treatment
since it is expected to lead to increased ﬁbrinolysis and thus re-
Fig. 5. Immunohistochemical detection of tenascin-C and ﬁbrin in tumor samples. Left panel shows hematoxylin and eosin staining (H&E), middle panel tenascin-C staining
and right panel ﬁbrin staining. Bar: 50 lm. for squamous cell carcinoma. Bar: 100 lm for lung carcinomas.
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lagen deposition since persistence of ﬁbrin within the alveolar
space may provide a provisional matrix for ﬁbroblasts allowing
the formation of collagenous scars [23].
3.6. Tenascin-C and ﬁbrin in tumors
Since tenascin-C is known to accumulate in cancer stroma, we
investigated whether the correlation between tenascin-C upregu-
lation and ﬁbrin accumulation was also relevant in tumors. We
stained successive sections of head and neck squamous cell carci-
noma as well as lung tumors for tenascin-C and ﬁbrin. We ob-
served a characteristic tenascin-C staining around tumor cell
nodules, in the tumor stroma. Fibrin staining appeared almost
superimposed to the tenascin-C staining (Fig. 5), supporting our
newly established link between tenascin-C and ﬁbrin accumula-
tion and conﬁrming similar observations in laryngeal and hypo-
pharyngeal cancer samples [27]. Our observation that tenascin-C
reduces plasmin activity looks at the ﬁrst view hard to reconcile
with the known characteristic of tumor cells to activate proteases
and digest the surrounding matrix to facilitate their migration. In-
deed, in addition to its impact on ﬁbrinolysis, plasmin impacts the
composition and function of extracellular matrix through the acti-
vation of matrix metalloproteases (for review see [28]), latent
growth factors [29,30] as well as pro-hormones. However, it is
known that during tumor stroma generation, plasma ﬁbrinogenextravasates from leaky blood vessels and clots in the extravascu-
lar place (for review see [31]. This provisional ﬁbrin matrix facili-
tates the migration of ﬁbroblasts [32], inﬂammatory cells [33]
and endothelial cells [34]. The ﬁbrinogen may not only derive from
blood, since cancer-associated ﬁbroblasts were shown to express
more ﬁbrinogen than control ﬁbroblasts [35]. With time, the ﬁbrin
matrix is gradually replaced by a more mature collagenous connec-
tive tissue [36]. Observing ﬁbrin and tenascin-C in close proximity
in head and neck squamous cell carcinomas and lung carcinomas is
especially interesting since ﬁrst tenascin-C accumulates at the
invasive front of tumors, where migration and invasion of cells oc-
cur, and second ﬁbrinogen/ﬁbrin is an important pro-metastatic
factor [37]. In contrast, high tPA-expression in primary melanoma
correlates with good prognosis [38]. In addition to its enzymatic
role, tPA has recently been described as a cytokine able to initiate
various intercellular signaling pathways through its binding to the
cell membrane LDL receptor-related protein 1 (LRP-1) [39]. It will
be of interest to investigate in which context upregulation of ten-
ascin-C could lead to inhibition of intercellular signaling pathways
triggered by tissue plasminogen activator.4. Conclusion
We found a correlation between tenascin-C and ﬁbrin deposi-
tion mechanistically linked to tPA regulation. We thus propose a
920 F. Brellier et al. / FEBS Letters 585 (2011) 913–920new role of tenascin-C in regulating the ﬁbrinolytic system which
opens new perspectives for the diagnosis and treatment of diseases
conditions associated with tenascin-C overexpression.
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